Terlipressin
- Generic Name
- Terlipressin
- Brand Names
- Terlivaz
- Drug Type
- Biotech
- CAS Number
- 14636-12-5
- Unique Ingredient Identifier
- 7Z5X49W53P
- Background
Terlipressin is a synthetic analogue of vasopressin, which is an endogenous neurohormone that acts as a vasoconstrictor. It is a prodrug of lypressin, or lysine vasopressin. Compared to endogenous vasopressin, terlipressin has a longer half life and increased selectivity for the V1 receptor. As a potent vasopressor, terlipressin has been investigated in various shock states and conditions with diminished vasomotor tone. It was also studied in hepatorenal syndrome (HRS) and variceal bleeding. The drug was first approved by the FDA in September 2022.
- Indication
Terlipressin is a vasopressin receptor agonist indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function. The US prescribing information states that patients with a serum creatinine > 5 mg/dL are unlikely to experience benefit from terlipressin.
- Associated Conditions
- Hepato-Renal Syndrome, Hepatorenal Syndrome Type 1, Oesophageal varices haemorrhage, Portal Hypertension
A Study of Terlipressin in Patients With Hepatorenal Syndrome Type 1
- First Posted Date
- 2011-06-15
- Last Posted Date
- 2012-02-14
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT01373606
- Locations
- 🇯🇵
Investigational site, Kanto, Japan
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
- First Posted Date
- 2010-06-14
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Mallinckrodt
- Target Recruit Count
- 196
- Registration Number
- NCT01143246
- Locations
- 🇺🇸
Scripps Clinic, La Jolla, California, United States
🇺🇸University of Kentucky Chandler Medical Center, Lexington, Kentucky, United States
🇺🇸Iowa City VA Health Care System, Iowa City, Iowa, United States
Terlipressin in Septic Shock: Effects on Microcirculation
- Conditions
- Septic ShockSepsis
- Interventions
- First Posted Date
- 2009-10-15
- Last Posted Date
- 2010-02-04
- Lead Sponsor
- University of Roma La Sapienza
- Target Recruit Count
- 60
- Registration Number
- NCT00995839
- Locations
- 🇮🇹
Departement of Anesthesiology and Intensive Care, Rome, I, Italy
Terlipressin in Cirrhotic Patients With Recidivation Ascites Treated With Paracentesis and Albumin
- First Posted Date
- 2009-09-30
- Last Posted Date
- 2015-06-15
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 82
- Registration Number
- NCT00986817
- Locations
- 🇫🇷
CARBONELL Nicolas, Paris, France
Comparison of Terlipressin, Somatostatin, and Octreotide for Control of Variceal Bleeding
- Conditions
- Variceal Bleeding, Cirrhosis
- Interventions
- First Posted Date
- 2009-08-26
- Last Posted Date
- 2018-03-19
- Lead Sponsor
- Korea University
- Target Recruit Count
- 1034
- Registration Number
- NCT00966355
- Locations
- 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of
Prevention of Esophageal Variceal Rebleeding
- Conditions
- Esophageal Variceal Rebleeding
- Interventions
- Drug: pantoloc (proton pump inhibitor)
- First Posted Date
- 2009-03-18
- Last Posted Date
- 2009-03-18
- Lead Sponsor
- National Science Council, Taiwan
- Target Recruit Count
- 120
- Registration Number
- NCT00863837
Terlipressin Administration in Septic Shock Refractory to Catecholamines
- First Posted Date
- 2008-11-19
- Last Posted Date
- 2008-11-19
- Lead Sponsor
- Assaf-Harofeh Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT00793559
- Locations
- 🇮🇱
Asaf Harofeh MC, Zrifin, Israel
Terlipressin Given As I.V. Boluses Versus Terlipressin Given As Continuous Intravenous Infusion In Patients With Cirrhosis And Type 1 Hepatorenal Syndrome
- Conditions
- CirrhosisType 1 Hepatorenal Syndrome
- Interventions
- First Posted Date
- 2008-08-28
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- University of Padova
- Target Recruit Count
- 70
- Registration Number
- NCT00742690
- Locations
- 🇮🇹
Liver Unit, General Hospital, Padova, Italy
Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome
- Conditions
- CirrhosisHepatorenal Syndrome
- Interventions
- First Posted Date
- 2008-08-27
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- University of Padova
- Target Recruit Count
- 49
- Registration Number
- NCT00742339
- Locations
- 🇮🇹
Dept. of Clinical and Experimental Medicine, University of Padova, Padova, Italy
Terlipressin in Septic Shock in Cirrhosis
- Conditions
- Liver CirrhosisSeptic Shock
- Interventions
- Drug: alpha adrenergic drugs
- First Posted Date
- 2008-03-04
- Last Posted Date
- 2016-02-24
- Lead Sponsor
- Hospital Clinic of Barcelona
- Target Recruit Count
- 72
- Registration Number
- NCT00628160
- Locations
- 🇪🇸
Hospital Clinic Barcelona, Barcelona, Catalonia, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.